Therefore, recent guidelines recommend GLP-1 RAs for patients with T2DM, established or high-risk atherosclerotic cardiovascular disease, and/or chronic kidney disease for glycemic management and comprehensive cardiovascular risk reduction [6,7]
No published study has linked BPC-157 to tumorigenesis, and Sikiric's group has explicitly noted the absence of neoplastic findings in chronic dosing models 1
Some peptides support fat loss and body composition, while others enhance recovery, skin elasticity, cognitive clarity, or hormone balance
29 July 2020
In the ATTAIN-1 trial, participants who received the highest dose of Foundayo and completed treatment lost an average of 27.3 pounds (12.4%), compared with only 2.2 pounds (0.9%) with placebo
Elucidating compound mechanism of action by network perturbation analysis